Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces the Publication of New Scientific Article in Biomedicine & Pharmacotherapy Which Further Strengthens its Phase III Development Plan in Difficult to Treat and Resistant Hypertension
May 19, 2021 12:40 ET | Quantum Genomics
PARIS, May 19, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Secures €3 Million Non-dilutive Financing
April 28, 2021 12:04 ET | Quantum Genomics
€1.5 million guaranteed by the French government (PGE) and granted by BNP bank €1.5 million innovation and R&D loan granted by Bpifrance Funding will allow for acceleration of R&D programs ...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Will Present Top-line Results From its QUORUM Study of Firibastat in Heart Failure Post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting
April 21, 2021 02:00 ET | Quantum Genomics
PARIS, April 21, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces the End of its Collaboration with Qilu for the Development and Commercialization of Firibastat in China
April 20, 2021 02:00 ET | Quantum Genomics
PARIS and NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Reports Full Year 2020 Operating and Financial Results
March 25, 2021 13:00 ET | Quantum Genomics
Recruitment of first subjects for Phase III trial in difficult-to-treat and resistant arterial hypertension patients Finalization of recruitment for Phase IIb trial in heart failure with upcoming...
Logo_Quantum_Genomics-iloveimg-resized.png
Orient EuroPharma Acquires Equity Stake in Quantum Genomics
February 09, 2021 12:00 ET | Quantum Genomics
PARIS and NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat
January 18, 2021 15:30 ET | Quantum Genomics
PARIS and NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Signs a Strategic Contract with Delpharm
December 16, 2020 02:00 ET | Quantum Genomics
PARIS and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
December 15, 2020 02:00 ET | Quantum Genomics
Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales Faran to receive an exclusive license to develop and commercialize firibastat...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm
December 02, 2020 11:50 ET | Quantum Genomics
Quantum Genomics to receive up to $18.5 million in upfront and milestone payments plus double-digit royalties on sales DongWha Pharm to receive an exclusive license to develop and commercialize...